Maiwald Magazine

News and Releases

Maiwald Blog

11 Apr 2025 - Maiwald Blog

EPO Board of Appeal 3.3.04 is setting the right standard for acknowledging novelty of non-medical use claims (T 1913/21)

G 2/88 provides legal assessment for novelty of a non-medical use claim. G 2/88 allows acknowledging novelty of a non-medical use claim of an old compound for a particular pur...

Continue reading

8 Apr 2025 - Maiwald Blog

EPO revokes Roche’s Patent on combination therapy of bevacizumab and paclitaxel for platinum-resistant ovarian cancer that was supported by results of Phase III AURELIA clinical trial

European Patent EP 2 825 558 concerns a combination therapy of bevacizumab and paclitaxel for platinum-resistant ovarian cancer. The claim was supported by Phase III AURELIA c...

Continue reading

17 Jan 2025 - Maiwald Blog

UPDATE: New proceedings before the Enlarged Board of Appeal: “G2/24 – Skin cleanser”

On the issue of the potential continuation of EPO appeal proceedings by an intervener the questions for referral on which we already reported

Continue reading

All articles

Press Coverage

25 Mar 2025 - Pressemitteilung

Roche gets Illumina unit’s DNA testing patent revoked

A European Patent Office board of appeal said in a ruling published on March 10th that Roche Diagnostics GmbH proved Verinata Health Inc.'s blueprint lacks an inventive step over an earlier international patent application setting out a similar way of testing "free-floating ...

Continue reading

11 Mar 2025 - Pressebericht

Roche gets Illumina unit’s DNA testing patent revoked

Roche has successfully persuaded a European appeals panel to revoke a patent held by Illumina’s subsidiary, Verinata Health, for detecting fetal DNA in maternal blood. The European Patent Office (EPO) ruled that the patent lacked an inventive step, as a prior application f...

Continue reading

12 Feb 2025 - Pressebericht

Royalty Pharma Announces $250M R&D Funding Collaboration with Biogen

New York, NY, February 12, 2025 – Royalty Pharma (Nasdaq: RPRX) has entered into an agreement with Biogen to provide up to $250 million in research and development (R&D) funding for litifilimab, a first-in-class investigational biologic in Phase 3 tria...

Continue reading

Maiwald in the press

Staff News

4 Feb 2025 - Personalnachricht

Maiwald congratulates Dr. Anna Closs on passing the exam

We congratulate Dr. Anna Closs on passing the German patent attorney examination!

Continue reading

8 Jan 2025 - Personalnachricht

Maiwald appoints Dr. Lukas Delvos and Dr. Jian Sun as Counsel

Effective January 1, 2025, Maiwald, one of Germany's leading intellectual property law firms, appointed two new Counsel, Dr. Lukas Delvos and Dr. Jian Sun. Lukas Delvos until ...

Continue reading

29 Nov 2024 - Personalnachricht

Maiwald congratulates on passing the exam

We would like to congratulate

Continue reading

All Staff News

Publications

22 Apr 2025 - Publikation

MAIinsight Issue 2 out now!

Continue reading

24 Mar 2025 - Publikation

Statistics and Takeaways from Continued Application of G 2/21 by the EPO’s Boards of Appeal and First Impressions from the UPC on “Plausibility” epi Information, 1/2025

In G 2/21 of March 23, 2023, the Enlarged Board of Appeal (EBA) decided on the requirements for reliance on a purported technical effect for supporting inventive step, which i...

Continue reading

10 Mar 2025 - Publikation

Germany permits service of claims on Chinese defendants by publication, Managing IP 2025

German courts now allow the service of claims on Chinese defendants by publication to ensure effective legal protection. The Regional Court of Frankfurt am Ma...

Continue reading

All publications

Awards

29 Apr 2025 - Auszeichnung

Maiwald voted one of the best commercial law firms of 2025 by brandeins and Statista

Using a two-stage survey and evaluation process that takes into account recommendations from lawyers, business and corporate clients, Statista, together with the business maga...

Continue reading

21 Feb 2025 - Auszeichnung

Chambers Germany 2025 rankings

We are proud to share that Chambers & Partners has ranked Maiwald in their inaugural 2025 Germany edition for

Continue reading

19 Feb 2025 - Auszeichnung

Managing IP EMEA Awards 2025: shortlists revealed

The Managing IP EMEA Awards 2025 shortlist has been unveiled, recognizing top law firms and practitioners across the region for their excellence in intellectual property. ...

Continue reading

All awards

Events

Tue.

6

6 May 2025 |Upcoming|External Events

Maiwald at the LSPN North America Spring 2025 in Boston, May 6-7, 2025

Maiwald is joining one of the most influential IP conference in the life sciencesThe 7th Annual LSPN North America–Spring Conference is an important destination for cutting-edge insights into intellectual property challenges in pharmaceutical, biotechnology, and medical technology industries.We are excited to announce that Maiwald is a

Continue reading

Thu.

15

15 May 2025 |Upcoming|SeminarSeminar

Maiwald Seminar on May 15

Patent law news: EPO case law, software and UPC (Lectures will be held in German) We are delighted to invite you once again to our Maiwald seminar. The presentations will take place on May 15, 2025 from 14:00 in Munich in our seminar room in our Maiwald office. ...

Continue reading

Sat.

17

17 May 2025 |Upcoming|External Events

Maiwald at INTA’s 2025 Annual Meeting in San Diego

Connect with more than 10,000 top intellectual property professionals, business leaders, government officials, judges, NGOs, and solutions providers at the largest IP gathering of the year. Once again, we are excited to be part of INTA 2025 in San Diego!

Continue reading

Wed.

21

21 May 2025 |Upcoming|External Events

C5’s 18th Annual Forum on “Pharma & Biotech Patent Litigation in Europe” in Amsterdam

We are pleased to announce that Dr. Eva Susanne Ehlich will be an expert at the 18th C5 Communications Forum on “Pharma & Biotech Patent Litigation in Europe” in Amsterdam. Eva will give a presentation on “Plausibility and Post-Publicatio...

Continue reading

All events